Shanghai Pharmaceuticals Holding Co. Ltd. has disclosed aza-ergoline derivatives acting as dopamine D2 receptor and/or D3 receptor agonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), depression, erectile dysfunction, substance abuse and dependence, restless legs syndrome, schizophrenia, Parkinson’s and Alzheimer’s disease, among others.

Enanta Pharmaceuticals Inc. has developed mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis, pulmonary arterial hypertension, irritable bowel syndrome, inflammatory, dermatological and respiratory disorders, among others.

Terremoto Biosciences Inc. has synthesized new 3H-imidazo[4,5-b]pyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKB-α) inhibitors reported to be useful for the treatment of cancer.

Astrazeneca has identified anthracycline compounds and antibody-drug conjugates consisting of an antibody covalently bound to anthracycline derivatives reported to be useful for the treatment of cancer.

Merck KGaA has patented substituted bicyclic transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TED interaction inhibitors reported to be useful for the treatment of cancer.

Previous research revealed that nuclear factor of activated T cells 1 (NFAT1) is a novel regulator of the mouse double minute 2 homolog (MDM2) oncogene, which acts by directly binding to the MDM2 P2 promoter and as such, enhancing MDM2 transcription independent of p53. Researchers from the University of Houston and Baylor College of Medicine presented preclinical data for MA-242, a dual inhibitor of MDM2 and NFAT1, being developed for the treatment of cancer.

Researchers from Sunrock Biopharma SL presented preclinical data on SRB-1, a CCR9-depleting antibody aimed to restore immune homeostasis in patients with inflammatory bowel disease.